Skip to content
Business

Roche Wins FDA Approval for Breast Cancer Pill Wilserdly After 62% Cut in Progression Risk

The FDA approved Roche's all-pill Wilserdly combination for ESR1-mutated advanced breast cancer after it cut the risk of progression or death by 62%. A ruling on early-stage use is due 30 November.

Roche Tower 1 and Roche Tower 2, the company's headquarters buildings in Basel, photographed in March 2021.
Photo: Achilaos, Wikimedia Commons, CC BY-SA 4.0

The US Food and Drug Administration approved Roche's Wilserdly (giredestrant) on Monday 16 November for advanced breast cancer that has stopped responding to hormone therapy, a treatment patients can take entirely as pills. In the evERA trial, Wilserdly paired with everolimus cut the risk of the cancer growing or the patient dying by 62% in people whose tumours carry an ESR1 mutation. A second FDA decision, on early-stage disease, is due on 30 November.

Wilserdly at a glance

  • 62% lower risk of progression or death in ESR1-mutated patients in the evERA trial
  • 10 months median time before the disease progressed, against 5.5 months on standard therapy
  • 30 November the date the FDA has set to decide on early-stage breast cancer

The FDA approved Wilserdly four weeks early

Roche had been waiting for an answer by 18 December, the goal date its US arm Genentech gave in September. The FDA said it approved the application four weeks ahead of that date, after a review run alongside Health Canada and Israel's Ministry of Health.

The label covers adults with oestrogen receptor-positive, HER2-negative breast cancer that is locally advanced or has spread, whose tumour carries an ESR1 mutation, and whose disease has come back or grown despite hormone treatment. The FDA also cleared a blood test, FoundationOne Liquid CDx, to find the patients who qualify.

The mutation is how many of these tumours escape. Oestrogen receptor-positive cancers feed on the hormone, so doctors starve them with drugs that block it. Over time, a change in the ESR1 gene can let the cancer keep growing anyway. Roche said up to 40% of patients with hormone receptor-positive metastatic breast cancer develop these mutations.

RO in the three months to 16 November 2026. Daily closing prices from exchange data.
RO in the three months to 16 November 2026. Daily closing prices from exchange data.

What the evERA trial showed

The evERA study enrolled 373 adults whose cancer had already been treated with hormone therapy and a CDK4/6 inhibitor, a class of pills used as a first treatment for advanced disease. Of those, 207 had ESR1 mutations. Patients were assigned at random: 183 got Wilserdly at 30 mg once a day, and 190 got their doctor's choice of exemestane, fulvestrant or tamoxifen. Everyone also took 10 mg of everolimus daily, a drug that blocks mTOR, part of a second growth pathway that cancer cells use to resist hormone treatment.

In the ESR1-mutated group, the FDA reported these results:

ESR1-mutated patientsWilserdly + everolimusStandard hormone therapy + everolimus
Median time without progression10 months5.5 months
Tumours that shrank (response rate)27%14%
Overall survivalNot yet matureNot yet mature

Across all 373 patients, Genentech reported in September a 44% cut in the risk of progression or death. The approval covers only the mutated group.

The most common side effects were mouth sores, rash, tiredness, diarrhoea, muscle and bone pain, lung inflammation and nausea. The prescribing information warns of a slow heart rate and of harm to an unborn baby.

"By pairing potent oestrogen receptor degradation with everolimus, Wilserdly offers a targeted, all-oral regimen that significantly delays disease progression and allows advanced breast cancer patients to take their treatment from home," said Levi Garraway, Roche's chief medical officer.

Rival drugs reached the market first

Wilserdly is an oral SERD, or selective oestrogen receptor degrader: a pill that blocks the receptor and makes the cell break it down. It is not the first drug for ESR1-mutated breast cancer. FDA records show approvals for Stemline's elacestrant (Orserdu) in January 2023, Eli Lilly's imlunestrant (Inluriyo) in September 2025 and Arvinas's vepdegestrant (Veppanu) in May 2026. In September 2026, AstraZeneca won accelerated approval for camizestrant (Etcamah), and Lilly added a combination of Inluriyo with its own drug Verzenio.

AstraZeneca: share price, chart and news

Roche is selling the combination. It said Wilserdly is the first next-generation all-oral SERD combination to beat a standard hormone combination head to head in a phase III trial in patients who have already had a CDK4/6 inhibitor. Genentech said the drug should be available in the US in the coming weeks.

A bigger decision is due on 30 November

The decision that could matter more comes in two weeks. Roche has asked the FDA to approve Wilserdly as adjuvant treatment, the therapy taken after surgery to stop the cancer coming back, for stage I to III disease at intermediate to high risk of recurrence. The filing rests on the phase III lidERA trial and is under priority review.

That pool of patients is far bigger. Roche said hormone receptor-positive, HER2-negative cancer makes up about 70% of breast cancers, and more than 90% of those cases are diagnosed at an early stage. If approved, Wilserdly would be the first new adjuvant hormone therapy in over 20 years, Roche said.

"We remain focused on maximising the clinical impact of Wilserdly across the continuum of care, including early-stage disease," said Teresa Graham, chief executive of Roche Pharmaceuticals.

Roche: share price, chart and news

What to watch next

  • 30 November: the FDA decision on early-stage use
  • The US launch, expected in the coming weeks
  • Overall survival data from evERA, still immature
  • Filings outside the US, which Roche said are under way

Questions and answers

What is Wilserdly used for?

Wilserdly (giredestrant) is a once-daily Roche pill, taken with everolimus, for adults with oestrogen receptor-positive, HER2-negative advanced breast cancer that carries an ESR1 mutation and has come back or grown despite hormone therapy.

How well did Wilserdly work in the evERA trial?

In patients with ESR1 mutations, it cut the risk of progression or death by 62% compared with standard hormone therapy, both given with everolimus.

When will the FDA decide on Wilserdly for early breast cancer?

The FDA has set 30 November 2026 to decide on Wilserdly as treatment after surgery for stage I to III breast cancer at intermediate to high risk of recurrence.

Sources

Related stories

Markets

Roche Shares Climb as Divarasib Cuts the Risk of Death by 44% in Lung Cancer

Roche shares opened about 1.5% higher on Monday after divarasib cut the risk of death by 44% against approved KRAS G12C drugs in a Phase III lung cancer trial, extending an 11.7%…

Markets

Roche's Sales Growth Speeds Up to 7% in the Third Quarter as It Confirms Its 2026 Outlook

Roche's third-quarter sales rose 7% at constant currencies and 8% in Swiss francs, taking nine-month sales to CHF 46.5bn. The group confirmed its 2026 targets as Xolair, Hemlibra…

Business

AstraZeneca Wins Klygefa Approval in US and EU, Plus a Third Bladder Cancer Use for Imfinzi

AstraZeneca won US and EU approval for Klygefa, a weekly self-injected drug for myasthenia gravis, and a US nod for an Imfinzi bladder cancer regimen that cut the risk of death by…

Business

Bayer Wins FDA Approval for Sunharbo, the First Factor XIa Blood Thinner in the US

Bayer shares rose about 1.5% to their highest since May 2023 after the FDA approved Sunharbo, the first Factor XIa blood thinner in the US, which cut repeat strokes by 26% in its…

Business

Québecor Makes a C$31bn Cash-and-Share Bid for Telus, Which Warns of Regulatory Risk

Québecor has offered C$6.35 in cash plus 0.17 of its own shares for each Telus share, a bid worth about C$31bn. The Telus board says the price falls short and the regulatory risk…

Business

Tyson Foods Shares Jump 8.7% as Beef Outlook Outweighs a $74m Quarterly Loss

Tyson Foods posted a $74m fourth-quarter net loss and adjusted EPS of $0.61, down 47%, yet its shares closed 8.7% higher on Monday as its 2027 beef outlook pointed to far smaller…

Business

ULA Loses Its First Mission as Vulcan Rocket Fails With 40 Amazon Leo Satellites on Board

United Launch Alliance's Vulcan rocket failed about 10 minutes after lift-off on Sunday, and all 40 Amazon Leo satellites were lost. Amazon fell 3.3% on Monday as space stocks…

Business

Tesla Plans €3bn Berlin Plant Expansion to Build Up to 1 Million Cybercabs a Year

Tesla plans to spend €3bn on a new hall at its Grünheide plant near Berlin that could build up to one million driverless Cybercabs a year, with production due to start in 2029.